본문으로 건너뛰기
← 뒤로

Engineered nanomedicine targets liver cancer stem cells to treat liver cancer disease.

1/5 보강
Journal of materials chemistry. B 📖 저널 OA 2.7% 2023: 0/1 OA 2024: 1/7 OA 2025: 1/24 OA 2026: 0/40 OA 2023~2026 2025 Vol.13(41) p. 13184-13205
Retraction 확인
출처

Huang F, Chen L, Zhang X, Tian S, Han Y, Hu M, He L, Luo R

📝 환자 설명용 한 줄

Liver cancer stem cells (LCSCs) are a population of cells with self-renewal and self-differentiation capacities, widely recognized as critical for hepatocellular carcinoma (HCC) development.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Huang F, Chen L, et al. (2025). Engineered nanomedicine targets liver cancer stem cells to treat liver cancer disease.. Journal of materials chemistry. B, 13(41), 13184-13205. https://doi.org/10.1039/d5tb01278c
MLA Huang F, et al.. "Engineered nanomedicine targets liver cancer stem cells to treat liver cancer disease.." Journal of materials chemistry. B, vol. 13, no. 41, 2025, pp. 13184-13205.
PMID 41002238 ↗
DOI 10.1039/d5tb01278c

Abstract

Liver cancer stem cells (LCSCs) are a population of cells with self-renewal and self-differentiation capacities, widely recognized as critical for hepatocellular carcinoma (HCC) development. Accordingly, eliminating LCSCs is considered a viable strategy for HCC treatment. However, conventional chemotherapy and radiation therapy struggle to eradicate LCSCs, underscoring the critical need for LCSC-targeted therapies. Nanotechnology offers unique advantages for LCSC targeting the selective delivery of drugs to tumor sites. Various engineered nanomedicines-including polymeric nanoparticles, biological nanomaterials, and inorganic nanoparticles-have been developed for their elimination. This article primarily reviews the biological concepts and biomarkers of LCSCs. In addition, it summarizes various strategies for targeting LCSCs using engineered nanomedicines.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (5)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반